New Blood Test Could Predict Alzheimer’s Risk
Dr. Jeremy Koppel, who co-leads the Litwin-Zucker Center, recently spoke about a groundbreaking new blood test that has the potential to foresee Alzheimer’s risk as much as a decade ahead. This test pinpoints high levels of a specific tau protein biomarker, P-tau217. Elevated P-tau217 levels suggest a greater likelihood of cognitive decline, which Koppel says could revolutionize early diagnosis and enhance our understanding of the disease’s progression.
A straightforward blood test capable of detecting a protein associated with Alzheimer’s might help estimate cognitive decline in older adults, potentially up to ten years before any noticeable symptoms manifest, according to a recent study.
This research, originating from Harvard and presented at the Alzheimer’s Association International Conference in London, potentially redefines how healthcare professionals evaluate dementia risk. It may even assist patients in better preparing for the disease.
By measuring the p-tau217 biomarker, which indicates the accumulation of harmful proteins in the brain, doctors could assess Alzheimer’s risk in a manner similar to using cholesterol tests for heart disease risk assessments.
In what stands as one of the largest studies of its kind, investigators monitored nearly 2,700 cognitively healthy adults around the age of 70 over a period of up to ten years.
The results showed that symptom-free individuals with very high levels of p-tau217 had about a 78% likelihood of developing cognitive impairment within ten years. Even those with moderate levels had a notable 45% risk over the same timeframe.
The p-tau217 is a modified version of tau, which is known to cause tangles in the brain linked to memory loss. This blood test offers additional insights beyond traditional brain scans and genetic assays, as noted by the researchers.
Rachel Buckley, the primary author of the study and an associate professor of neurology at Harvard Medical School, said the findings provide strong evidence that dementia risk can indeed be identified well before memory issues become apparent.
She emphasized that once this blood test is validated, it could be instrumental in selecting patients for clinical trials aimed at preventing cognitive decline and dementia.
Going forward, if treatments for early-stage Alzheimer’s receive approval, these tests might greatly assist with monitoring, treatment choices, and providing guidance for patients and their families.
However, researchers advised that the p-tau217 alone cannot fully determine an individual’s future risks. Elements like age, genetics, kidney function, and racial background may also impact biomarker levels and overall dementia risk.
The team highlighted the necessity for extended studies involving more diverse populations to refine these risk assessments.
Maria Carrillo, the chief science officer at the Alzheimer’s Association in Chicago, remarked that focusing on the asymptomatic phase of the disease, before memory issues surface, could be where future advancements in treatment would be most impactful.
She mentioned that identifying at-risk individuals earlier could significantly shift the ways we diagnose and treat dementia, potentially enabling interventions long before symptoms appear.
